ESC 365 - The impact on CD146 congestion biomarker by early adding SGLT2i dapaglifozin to intravenous loop diuretic in patients with acute heart failure

Open Access

The impact on CD146 congestion biomarker by early adding SGLT2i dapaglifozin to intravenous loop diuretic in patients with acute heart failure

Session: Congestion, SGLT2 inhibitors and novel therapies

Topic: Pharmacotherapy

Speaker: Doctor I. Lala (Arad, RO)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Ioan Radu Lala

Spitalul de Pneumoftiziologie si Boli Infectioase Victor Babes Timisoara, Arad (Romania)

1 follower

5 more presentations in this session

Optimisation of renin-angiotensin-aldosterone system inhibitors use in chronic kidney disease patients with heart failure: is hyperkalaemia a barrier?

Speaker: Professor E. Kelepouris (Philadelphia, US)

Factors influencing the up-titration to 10 mg target dose of vericiguat: data from a large observational cohort-study in the US.

Speaker: Doctor A. Michel (Basel, CH)

Addition of sodium-glucose cotransporter-2 inhibitors on steroidal mineralocorticoid receptor antagonists eliminates hyperkalemia risk in diabetic heart failure patients with chronic kidney disease

Speaker: Assistant Professor A. Sahin (Sivas, TR)

Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis

Speaker: Professor D. D'Amario (Novara, IT)

Introduction and optimization of the guideline-directed medical therapy in patients hospitalized for acute heart failure (OPTICARD)

Speaker: Doctor G. Baudry (Nancy, FR)

Access the full session

Congestion, SGLT2 inhibitors and novel therapies

Speakers: Doctor I. Lala, Professor E. Kelepouris, Doctor A. Michel, Assistant Professor A. Sahin, Professor D. D'Amario...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources